ArticleJCO oncology advances2026
Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.
Article in JCO oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03907488 (A Phase III, Randomized Study of Nivolumab), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeS1826 was an international phase 3 randomized trial that demonstrated improved progression-free survival of nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) over brentuximab vedotin plus AVD (BV+AVD) in newly diagnosed advanced stage classic Hodgkin lymphoma (cHL). Here we report results of enrolled participants with HIV. PARTICIPANTS AND
methodsPeople with HIV (PWH) with a CD4
results16 eligible PWH were enrolled, 11 received N+AVD and 5 received BV+AVD. The median follow-up duration was 32.7 months in the N+AVD arm and 26.7 months in the BV+AVD arm. The 2-year PFS rate was 77.9% in N+AVD arm and 75.0% in the BV+AVD arm. The 2-year OS was 85.7% in the N+AVD arm and 75.0% in the BV+AVD arm. Grade ≥ 3 adverse events were observed in 45% of participants in the N+AVD arm and 50% in the BV+AVD arm with more frequent febrile neutropenia, and severe infections observed in the BV+AVD arm.
conclusionsN+AVD is safe and effective in newly diagnosed HIV-associated advanced stage cHL. Clinicaltrials.gov number NCT03907488.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.